drugset / Trial / NCT04956302
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Panobinostat may stop or slow multiple myeloma by blocking the growth of new blood vessels necessary for cancer growth. Giving panobinostat in combination with daratumumab, bortezomib and dexamethasone may work better in treating relapsed/refractory multiple myeloma.
Timeline
- Start
- 2021-09-27
- Primary completion
- 2022-06-16
- Completion
- 2022-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | — | Oral |
| Background | Bortezomib | Small molecule | — | Subcutaneous |
| Background | Daratumumab and Hyaluronidase-fihj | Unknown | — | Subcutaneous |
| Background | Dexamethasone | Small molecule | — | Oral |